Users online: 1234    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 5
First page : ( 2310) Last page : ( 2314)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00416.3

Teneligliptin as an add on Therapy to Oral Anti diabetic agents in type 2 Diabetes Mellitus

Varghese Leena1,*, Murthi K.2, Pandey K.3

1KMCH College of Pharmacy, Coimbatore

2Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur-844102, India

3Rajendra Memorial Research Institute (RMRI), Patna

*Corresponding Author E-mail: leena28492@gmail.com

Online published on 16 June, 2020.


A study was conducted on a novel dipeptidyl peptidase-4 inhibitor, Teneligliptin when given as an add on therapy with oral anti diabetic agents in patients with type 2 diabetes mellitus. Previously diagnosed subjects with type 2 diabetes (T2DM) were assigned 20 mg/day teneligliptin along with other anti-diabetic drugs. At 3 months, levels of glycemic parameters like HbA1C, fasting blood glucose levels, Post Prandial levels as well as non-glycemic parameters like lipid profile (Total cholesterol, LDL, HDL, Triglycerides), hsCRP level, serum creatinine, Blood urea, BMI were compared with those at baseline. Teneligliptin as an add on therapy led to significant reduction in glycemic parameters like HbA1c (1.6±0.97mg/dl), fasting blood glucose (45.86±62.85), and post prandial levels (72.73±47.97) from the baseline values (p <0.000). Significant co relation was observed between change in HbA1c level and baseline HbA1C levels. Significant reduction in the total cholesterol levels were observed (p < 0.000) but other lipid profile parameters like HDL, LDL, and triglycerides were not shown to be statistically significant after treatment. No change in hsCRP level and BMI was observed. Addition of teneligliptin to oral anti diabetic agents led to a significant improvement in glycemic control in subjects with type 2 diabetes mellitus without causing any weight change.



Teneligliptin, DPP4 inhibitor, Type 2 Diabetes mellitus, Anti diabetics.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
598,056,726 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.